capacity to cross the endothelial barrier might have a higher metastatic potential. The goal of our project is to evaluate the possibility to preassess the metastatic potential of cancer cells derived from primary PCa patient using a microvasculature on chip device.
INTRODUCTION AND OBJECTIVES: We previously described a prostate-specific Pten knockout mouse with a genetically engineered luciferase reporter to monitor disease progression with BLI (Svensson et al, 2011, Am J Path) . Here, we describe two Pten/Trp53 DOKO models of prostate cancer with genetically engineered luciferase reporters to monitor disease progression with BLI.
METHODS: We generated 3 cohorts of Probasin (Pb)-Cre mediated Pten -/-combined with either Trp53 þ/þ (WT), Trp53 AE (HET), or Trp53 -/-(DOKO) mice on an albino C57BL/6 background with a Cre-activatable luciferase reporter allele. An additional inducible DOKO model was created by intraprostatic injection of CMV-Cre or Keratin-5 (K5)-Cre adeno-associated virus. The virus with the CMV promoter will induce broad Cre expression in the prostate, while the K5 will be targeted to the basal cells. BLI was measured biweekly starting at 5 weeks of age for the Pb-Cre mice and after injections for the viral Cre mice. We analyzed BLI data and histopathology for each of the cohorts.
RESULTS: The Pb-Cre DOKO mice develop large, locally invasive tumors that grow more quickly than the HET or WT genotypes. This difference is evident on BLI at 21 weeks of age (p[0.0009). The DOKO mice also have shorter survival compared to the HET or WT, with a median survival of 26.5 weeks compared to 50 and 41 weeks for WT and HET mice (p<0.0001). Pathologic analysis of the 3 groups showed sarcomatoid carcinoma in all DOKO mice, 41% of HET mice, and none of WT mice; high grade murine prostatic intraepithelial neoplasia (mPIN) in 35% of HET and 73% of WT mice; and low grade mPIN in 11% of HET and 13% of WT mice. There was invasion around pelvic lymphatics, but there was no pathologic confirmation of metastasis. To test androgen sensitivity, we castrated a separate cohort of Pb-Cre DOKO mice at age 10 weeks. BLI signal reached a nadir at 14 weeks but increased steadily to levels comparable to their non-castrate, age-matched counterparts. The Pten/Trp53 DOKO mouse cohorts with virally induced Cre are still active. Three out of five CMV-Cre mice have developed tumors evident on BLI at week 9; 2 of these were fatal at week 11. Of the K5-Cre mice, 2 out of 7 have tumors evident on BLI at week 11, and all are alive at present.
CONCLUSIONS Previously our laboratory identified ER-a and estrogen receptor-b (ER-b) in prostate stem cells (PSC). On PSC, estrogen activation of ER-a stimulates PSC to self-renew, whereas estrogen activation of ER-b inhibits PSC self-renewal, acting as a "brake" for PSC homeostasis. Further work found that ER-a down-regulates ER-b in PSC thus forming a tight regulatory loop for controlling PSC self-renewal by estrogens. As such, increased PSC ER-a levels reduce ER-b levels. This effectively removes the "brake" to enable an increase in PSC selfrenewal. Importantly, estrogen exposure has also been shown to promote prostate carcinogenesis. The objective of this study was to determine if SPOP & BRCA1, via ER-a selective E3 ligase activity, regulate PSC ER-a levels and whether this affects PSC proliferation.
METHODS: Primary cultures of normal human prostate epithelial cells (PrEC) were grown in a prostasphere-based, bromodeoyuridine (BrdU) label-retention assay that permits identification of initiating stem cells within the prostasphere (PS). PrEC were subjected to ER-a selective E3 ligase knockdown with siRNA transfection (SPOP and/or BRCA1), confirmed by RT qPCR. Fluorescence immunocytochemistry (ICC) was used to visualize ER-a & ER-b protein levels in BrdU labeled stem cells, and quantified with Image J software.
RESULTS: SPOP & BRCA-1 knockdowns in PrEC and prostaspheres were achieved with a mean 29% (8-54%) efficiency and mean 21% (9-36%) efficiency, respectively. ICC revealed a statistically significantly elevated level of ER-a in BrdU label-retaining stem cells of both SPOP and BRCA1 knockdowns compared to scramble siRNA controls. ICC also revealed a statistically significantly suppressed level of ER-b in BrdU label-retaining stem cells of both SPOP and BRCA1 knockdowns compared to scramble siRNA controls.
CONCLUSIONS: The results indicate that both SPOP & BRCA1, via ER-a selective E3 ligase: activity, regulate ER-a levels which in turn affects ER-b levels in PSC. Results also indicate that these alterations lead to changes in the ability of PrEC to form PS, indicating changes in PSC self-renewal capacity. We propose that functional SPOP & BRCA1 mutations may lead to higher stem cell ER-a expression, which may be pro-oncogenic in primary PCa.
